Epigral bets ₹600 cr on epoxy resins in strategic pivot
The chemicals company posted a 25% profit jump in Q1 and announced a capex equal to 12% of market cap to enter epoxy resins, drawing over half the input value from internal production.
— 3 earlier stories on Epigral Ltd. →What's new
- Epigral board approved ₹600 cr capex for epoxy resin capacity of 125 KTPA and derivatives.
- Q1 net profit rose 25% YoY to ₹99 cr; revenue up 15% to ₹709 cr; EBITDA margin 25%.
- Over 50% of raw material for the project will come from existing epichlorohydrin and caustic soda.
Why this matters
This is the biggest single bet in Epigral's recent history. The capex is 12% of market cap and shifts the company into higher-value epoxy resins, a market driven by renewable energy and electronics. The backward integration gives it a structural cost edge over peers who buy inputs.
What we're watching
- Pilot plant by Q2 FY27 -- a go/no-go test for the full-scale project.
- How the debt-equity ratio (~0.25) evolves as the capex gets funded.
- Customer traction from the automotive and renewable energy sectors.
The full read
Epigral posted a clean set of Q1 numbers: net profit up 25% to ₹99 crore on revenue of ₹709 crore, with an EBITDA margin of 25%. But the real news is the board's decision to spend ₹600 crore (equal to 12% of market cap) on a strategic entry into epoxy resins and formulations. The 125,000-tonne-per-annum plant will sit behind Epigral's existing epichlorohydrin and caustic soda lines, with over half the raw material value sourced internally. That backward integration gives it a margin advantage that pure-play epoxy makers cannot match. The first milestone is a pilot plant by Q2 FY27; commercial production is set for H2 FY28. The debt ratio is low at 0.25, so the funding math works even if part of the outlay is debt-financed. Execution risk is real, but this is the sort of pivot that rewrites a company's growth profile when it works. It won't be immediate, and the open question is whether customer approvals come through on schedule. But the direction is clear.
Questions answered
- How big is the ₹600 crore capex relative to Epigral's size?
- It represents roughly 12% of the company's current market cap of ₹4,772 crore and about 21% of its annualised revenue run-rate.
- What raw materials is Epigral contributing from its own production?
- Epigral already makes epichlorohydrin and caustic soda, both critical inputs for epoxy resins. The company says over half the raw material value for the new plant will be sourced internally.
- When will the epoxy plant start commercial production?
- The board has targeted commissioning by the second half of fiscal 2028. A pilot plant will be set up by Q2 FY27 to validate processes.
- Does Epigral have the balance sheet to fund this without strain?
- Its debt-to-equity ratio is low at 0.25 and trailing ROE is 14.9%. The capex is large, but the company has room to take on additional debt without excessive leverage.
- What demand drivers does Epigral see for epoxy resins?
- The company is targeting growing demand from renewable energy, electronics, automotive, and infrastructure sectors, all of which consume epoxy-based coatings, adhesives, and composites.
Story so far
All notes on EPIGRAL →- 27 Jul 2026 · 2:15 PM IST Epigral bets ₹600 cr on epoxy resins in strategic pivot
- today Epigral enters epoxy resins with two Dahej plants, capex undisclosed
- today Epigral Q1: Revenue up 16%, adjusted PAT jumps 24%
- today Epigral logs 16% revenue growth in Q1; PAT falls on one-time credit base effect